clinical trials |
News, Publications, and Related Stories
U.S. News & World Report -- April 21, 2010 Having dense breasts has long been known to increase a woman's risk for breast cancer, and new research confirms that a decline in breast density over time does, in fact, decrease that risk. This story has been covered by several international and national outlets. View Related 
Discovery's Edge -- Mayo Clinic's Research Publication Molecular breast imaging (MBI) is three times more effective than mammograms, but far less costly than other nuclear-medicine imaging. View Related 
HealthDay -- March 16, 2010 Study lead author Dr. David A. Woodrum, interventional radiologist at the Mayo Clinic in Rochester, Minn. View Related 
HealthDay -- March 12, 2010 Lead investigator Dr. Johnny Ray Bernard Jr., a radiation oncologist at the Mayo Clinic in Jacksonville, Fla. View Related 
In the News: Extensive Lymph Node Removal May Improve Survival in Some Women with Endometrial Cancer
NCI Cancer Bulletin -- March 9, 2010 Drs. Sean Dowdy and Andrea Marini View Related 
Oncology Times -- Feb. 25, 2010 Dr. Edith Perez, Director of Mayo Clinic's Breast Program and Chair of the Clinical Study Unit at Mayo Clinic Jacksonville (FL) View Related
USA Today -- Feb. 24, 2010 Matthew Goetz, M.D., hoped to settle the debate about whether CYP2D6 status affects tamoxifen users' recurrence risk. View Related 
MedCity News -- Jan. 14, 2010 Dr. Sandhya Pruthi says mammograms are still the best screening tool to reduce breast cancer deaths. View Related
Mayo Clinic Health Letter -- Jan. 4, 2010 Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. View Related 
Med Page Today -- Dec. 22, 2009 Edith Perez, M.D., Mayo Clinic, Jacksonville, Fla., comments on the study results. View Related 
Los Angeles Times -- Dec. 12, 2009 Lead researcher: Edith Perez, M.D., Mayo Clinic in Jacksonville, Fla. View Related 
Wall Street Journal -- Nov. 19, 2009 Sandhya Pruthi, M.D., director of Mayo Clinic Breast Clinic, Rochester, Minn., answers questions related to these new guidelines. View Related 
Mayo task force says women 40 and older should be screened as per usual Mayo Clinic will continue to recommend screening mammograms for women age 40 and older. "Everyday we discover invasive breast cancer in a woman age 40–50," says Sandhya Pruthi, M.D., director of the Breast Clinic at Mayo Clinic in Rochester, and leader of the task force. View Related
UPI -- Nov. 16, 2009 Refers to the Special Report on Cancer Prevention in the November issue of Mayo Clinic Women's HealthSource View Related
Co-Leaders of Two Cancer Center Programs Were Among Those Honored Cancer Center recipients are Charles Loprinzi, M.D., co-leader of the Cancer Prevention and Control Program and Rafael Fonseca, M.D., co-leader of the Hematologic Malignancies Program. View Related 
Mayo Clinic Women's HealthSource - October 2009 Mayo Clinic Women's HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. View Related 
Researchers say this method is more accurate in predicting risk for an individual than the Gail model. View Abstract 
Mayo Clinic Women's HealthSource Mayo Clinic Women's HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. View Related
Event: Rochester, Minn. 
It is the seventh SPORE grant that Mayo has received to support cancer research. "The Mayo Ovarian Cancer SPORE is uniquely poised to address key challenges in ovarian cancer," says Lynn Hartmann, M.D., lead investigator of the newly awarded SPORE. "Our balance of basic, population science and clinical research programs within the Mayo Clinic Cancer Center enables us to pursue major issues in ovarian cancer, such as chemotherapy resistance, and quickly move new approaches into the clinic." View Related 
Patient Story -- Rolande Graves Professor Rolande Graves has faced her breast cancer the way she has faced any obstacle — with determination and a positive attitude. View Related 
Offering cancer patients in Florida and the Southeast access to investigational therapies through rigorously monitored clinical trials "The cancer field is rapidly moving to use of these new agents as a way to improve upon the success we have seen with more traditional therapies, such as chemotherapy and radiation," says says Michael Menefee, M.D., who heads the Phase I Clinical Trial Program in Oncology at Mayo Clinic, Jacksonville. View Related 
Mayo Clinic Health Letter -- July 2009 Mayo Clinic Health Letter is an eight-page monthly newsletter of reliable, accurate and practical information on today's health and medical news. View Related 
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center. 
Presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). A combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial as other current options — and doesn't cause hair loss in patients. View Abstract 
Medical Edge Newspaper I have the BRCA1 mutation ("breast cancer gene"), which I know increases my risk of getting breast cancer as well as ovarian cancer. A gynecologist recommends I have my ovaries removed as soon as I'm done having children, but another doctor suggests waiting until I'm closer to 40 (I'm 32 now). Are there pros and cons of each option, or is one doctor right? View Related 
Mayo Clinic Women's HealthSource -- March 2009 Mayo Clinic Women's HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. View Related 
Patient Story -- Mary Berman Dr. Mary Berman found herself "mesmerized with Mayo" when she was treated for breast cancer. View Related 
Discovery's Edge Tamoxifen is an anti–estrogen drug that almost halves the return of cancer and reduces the mortality rate by one–third in women with early breast cancer. It is so effective that it has achieved status as somewhat of a miracle drug. However, there is a large group of women who have been taking tamoxifen who might as well have been taking a sugar pill. Three Mayo research teams are collaborating to find the best drugs for these patients. View Related 
Medical Edge Newspaper I recently heard in the news about a new breast cancer detection method that, according to the report, is really promising. Is this going to replace the mammogram? View Related 
Presented at the annual San Antonio Breast Cancer Symposium. "These new results validate our earlier findings," says the study's lead investigator, Matthew Goetz, M.D., an assistant professor of oncology and pharmacology at Mayo Clinic, "and strongly suggest that going forward, postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 before beginning therapy." View Related
Presented at the annual San Antonio Breast Cancer symposium. "Breast cancer is the leading cause of cancer death in women age 25 to 49, and these young patients also have worse overall survival and increased risk of cancer coming back compared to older women, so it is important that we try to understand how the cancer develops and the measures that help prevent it," says the study's lead investigator, Karthik Ghosh, M.D. View Related 
"Tamoxifen is a good drug, but it looks like aromatase inhibitors may be somewhat better," says James Ingle, M.D., a professor of oncology at Mayo Clinic, who presented the results on behalf of the Aromatase Inhibitors Overview Group (AIOG). Presented at the 2008 San Antonio Breast Cancer Symposium. View Abstract 
Presented at the annual San Antonio Breast Cancer Symposium. "Tens of thousands of women in this country are prescribed tamoxifen for either treatment or prevention of breast cancer, and while it has shown remarkable success, it does not work for a substantial number of patients," says the study's lead investigator, John Hawse, Ph.D. "These findings increase our understanding of tamoxifen and, we hope, could pave the way for improved therapies." View Related 
"An anti-p120 agent could provide a much-needed double whammy — stop cancer spread and shut down growth at the same time," says the study's lead investigator, Panos Anastasiadis, Ph.D., a Mayo Clinic cancer researcher. Available online in the November issue of the Journal of Cell Biology. View Abstract
Publication: The Journal of Cell Biology -- Nov. 17, 2008 
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer." View Abstract 
Patient Story -- Debbie Baselle When Debbie Baselle learned about a Mayo Clinic clinical trial to control hot flashes, she was eager to sign up. View Related 
About 7.4 percent of U.S. women have asthma. The study found that the prevalence of asthma among breast cancer patients with recurrence of their disease as metastases in the lung is two-fold higher than among non-asthmatic women with breast cancer. "If you are a breast cancer patient with asthma, taking your anti-inflammatory inhaled steroids may be more important to you than simply stopping your wheezing" says James Lee, Ph.D., a Mayo Clinic researcher in Arizona and the senior author of the study. View Abstract 
Patient Story -- Jan Hawkes When Jan Hawkes was diagnosed with breast cancer, maintaining her active lifestyle meant coordinating care between Mayo Clinic campuses in Rochester, Minn., and Arizona. View Related 
Medical Edge Newspaper I have a niece who's 15. Her mother died of inflammatory breast cancer at age 27. Her maternal grandmother died of cancer at age 37. Do you recommend gene testing? Will a positive result affect her insurance coverage? When and how should we start monitoring? View Related 
Patient Story -- Regina Hamilton An MR-guided biopsy found Regina Hamilton's breast cancer months before other diagnostic tools could have. View Related 
Medical Edge Newspaper I started taking Premarin daily after a hysterectomy at age 46. I had difficulty getting a prescription for the drug, but continued to use it when I could. At age 67, I was put on a daily dose again. At 77, I feel great, but I'm wondering — what is the effect of all these years on the medication? View Related 
Potentially, this vaccine could be used as a complementary tool with tamoxifen, a widely used estrogen therapy used as a temporary post-treatment approach to prevent the return of tumors. Breast cancer is second only to lung cancer as a killer of women. In 1998-2002, according to the American Cancer Society, 95 percent of new cases and 97 percent of deaths occurred in women 40 and older in the United States. However, early diagnosis and treatment have led to increasing survival rates in the last 25 years. There are more than two million breast cancer survivors in the United States today. Breast cancer is second only to lung cancer as a killer of women. In 1998-2002, according to the American Cancer Society, 95 percent of new cases and 97 percent of deaths occurred in women 40 and older in the United States. However, early diagnosis and treatment have led to increasing survival rates in the last 25 years. There are more than two million breast cancer survivors in the United States today. View Related 
Publication: Cancer Research -- June 15, 2008 
Patient Story -- Sharon Francis Sharon Francis was working on a new design collection when the pain started. View Related 
Medical Edge Newspaper I am 52. I had a total hysterectomy and cervix removal at age 38. Do I still need to get a pelvic exam and Pap smear? I get a 50/50 answer from peers and medical personnel. Which is it and why? View Related 
Patient Story -- Susan Quinn Strong faith and medicine brought an ovarian cancer patient back to health. View Related 
Patient Story -- Tea Allegri It is a long trip from Caracas, Venezuela, to Rochester, Minn., but quality and efficiency motivate Tea Allegri and her husband, Luigi, to travel to Mayo Clinic when they have a serious problem. View Related 
Mayo Clinic Women's HealthSource -- April 2008 Mayo Clinic Women's HealthSource is published monthly to help women enjoy healthier, more productive lives. Revenue from subscriptions is used to support medical research at Mayo Clinic. View Related 
The research team discovered that women whose atypia tissue expressed COX-2 enzymes were more likely to develop breast cancer subsequently, and that the more the enzyme expressed, the higher the risk. View Abstract 
Patient Story -- Wanda Bowen Wanda Bowen appreciates the close monitoring of the Executive Health Program. View Related 
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study) "There have been major improvements in the management of patients with early breast cancer in the last few years, so this new study builds on this knowledge and sets an example of the new era: good science, good worldwide collaboration," said Edith Perez, M.D., an oncologist in the North Central Cancer Treatment Group (NCCTG) at Mayo Clinic in Jacksonville, Fla., who will lead the study for TBCI. View Related
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related 
Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Sandra Gendler, Ph.D., was named the David F. and Margaret T. Grohne Research Professor in Therapeutics for Cancer Research. Richard Vile, Ph.D., a consultant in the Department of Molecular Medicine and Department of Immunology at Mayo Clinic Rochester, was honored with The Richard M. Schulze Family Foundation Professorship.
Research into the B7 molecules has been a "family affair" at Mayo. Many Mayo immunologists have joined together to tackle various aspects of their function and behavior and have discovered how they function. 
Sound waves may help early detection of heart failure caused by Trastuzumab "Breast cancer is the second most common form of cancer in women, and the leading cause of death," says Bijoy K. Khandheria, M.D., chair, Mayo Clinic Cardiovascular Services, researcher and co-investigator of the study. "Anticancer drugs like Trastuzumab have substantial benefits, but in some patients the anticancer drug cross-reacts with the heart muscle. Therefore, methods to detect and halt heart muscle damage is therefore urgently required." View Abstract 
Patient Story -- Janet Vittone Janet Vittone, M.D., two sisters and her mother were diagnosed with breast cancer in the same year — and received the same swift treatment at Mayo Clinic. View Related 
Discovery's Edge "When we examined human breast tissue we were blown away by how dramatic and obvious the centrosome abnormalities were in the tumors," says Jeffrey Salisbury, Ph.D. "And that was literally on day one." View Related
Medical Edge Television Every day up to two-thousand women have hysterectomies. Many of these women also choose to have their ovaries taken out at the same time to remove their risk of ovarian cancer. But for younger women who are not at high risk for ovarian cancer, doctors at Mayo Clinic are saying, "not so fast." Two studies show that keeping your ovaries until after menopause may protect you from memory problems and Parkinson's disease. 
Phase 2 Consortium clinical trial shows promising results Presented by the study's primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer. "We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising." View Abstract
Medical Edge Radio For more information on inflammatory breast cancer treatment at Mayo Clinic, visit http://www.mayoclinic.org/inflammatory-breast-cancer Read Script 
Publication: Journal of Clinical Oncology -- Jan. 20, 2007 North Central Cancer Treatment Group View Related 
Medical Edge Television There is a type of breast cancer that often doesn't show up on mammograms. It's called inflammatory breast cancer. IBC can be stopped if you know the signs and symptoms. 
Publication: Journal of Clinical Oncology -- Aug. 1, 2006 A companion study to the National Cancer Institute of Canada Clinical Trials Group study MA.17 View Related 
Medical Edge Television Doctors at Mayo Clinic did a study to find out if giving women information before they have a mammogram makes a difference in their experience. 
Publication: Journal of Clinical Oncology -- July 1, 2006 North Central Cancer Treatment Group View Related 
Medical Edge Television One in eight. Those are the odds that your mom, sister, wife or friend has of getting breast cancer in her lifetime. The risk goes way up if you have one of two known breast cancer genes. 
Publication: Journal of Clinical Oncology -- June 20, 2006 North Central Cancer Treatment Group clinical trial View Related
Publication: Mayo Clinic Proceedings -- June 2006 The results suggest that providing women scheduled for screening mammograms with physician-approved educational material before their appointment significantly increases knowledge about screening mammography, risks and benefits, and possible follow-up. View Related
Mayo Clinic’s Molecular Medicine Program has three gene therapy clinical trials open in which the entire preclinical cycle—concept, discovery of agent, vector manufacture, toxicology and efficacy studies, and new drug application—was conducted at Mayo The projects engineered strains of the measles virus, MV-CEA and MV-NIS, which kill multiple cancer cells, and can be monitored easily. The open trials are in ovarian cancer, glioblastoma multiforme (brain cancer), and multiple myeloma. This article discusses the general research and the first trial which opened -- ovarian cancer. The projects are a fine example of a clear translational effort from bedside to bench and back to the bedside.
Medical Edge Television Ten years ago, 48,000 women -- mothers, wives, sisters -- died every year from breast cancer. Today, that number has dropped to 40,000. But it's still too high. That's why many women who are at high risk of getting breast cancer choose genetic testing.
Publication: Journal of Clinical Oncology -- Sept. 15, 2004 North Central Cancer Treatment Group clinical trial View Related
Publication: Journal of Clinical Oncology -- June 15, 2004 North Central Cancer Treatment Group with National Cancer Institute of Canada View Related 
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
